White Papers

  1. Achieving End-To-End Clinical Supply Chain Visibility 9/23/2025

    Transform supply chain management by integrating technology solutions and real-time insights to link patient-level data with upstream manufacturing operations.

  2. A Guide To Streamlining Study Start-Up In Australia 9/23/2025

    Discover the benefits of Australia as a premier destination for multinational sponsors looking to expedite drug development, refine trial design, and establish long-term research partnerships.

  3. The Hidden Problem In Early Phase Oncology Trials 9/23/2025

    Integrating patient-reported outcome measures (PROMs) can enable improved capture tolerability and optimize dosing decisions.

  4. A New Blueprint For Transforming Feasibility And Recruitment 9/22/2025

    Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.

  5. Phase 1 Clinical Trial Designs And Strategies 9/18/2025

    With tailored guidance, sponsors can align their modern model-based and model-assisted design choices to program goals, accelerating progress while safeguarding patients.

  6. Everest Group Life Sciences eCOA Peak Matrix Assessment 2025 9/16/2025

    Discover how digital platforms are revolutionizing clinical trials by improving data quality and patient engagement in this comprehensive market assessment.

  7. Advancing Alzheimer's Disease Therapies 9/3/2025

    By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.

  8. De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital 9/3/2025

    For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.

  9. Writing An IND Module 3 For Cell And Gene Therapy Products 9/1/2025

    This whitepaper outlines the critical considerations for CGT Investigational New Drug (IND) Module 3, as well as how to avoid clinical holds and ensure regulatory readiness.

  10. Enhancing Clinical Trial Flexibility 9/1/2025

    Once seen primarily as staffing extensions, FSPs have evolved into strategic partners that deliver flexibility, scalability, and tailored expertise.